MedTrace Logo

Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects

NCT04746287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2022-05-04

No results posted yet for this study

Summary

This is a first-in-human study of CKD-510 in single-ascending dose and multiple-ascending dose in healthy subjects. This trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of food effects of CKD-510.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CKD-510 single dose

Investigational drug

DRUG

CKD-510 food effect

Investigational drug

DRUG

CKD-510 multiple dose

Investigational drug

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2021-08-24
Completion
2021-08-24

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746287 on ClinicalTrials.gov